Roche/Genentech, OSI to pay $67M to Settle Drug Claims
The claims alleged that between 2006 and 2011, the companies misrepresented Tarceva (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 8, 2016 Category: Pharmaceuticals Source Type: news
Roche receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer
Roche announced today that the European Commission has approved the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR)-activating mutations. (Source: Roche Investor Update)
Source: Roche Investor Update - June 8, 2016 Category: Pharmaceuticals Source Type: news
Roche receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer
Roche announced today that the European Commission has approved the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR)-activating mutations. (Source: Roche Media News)
Source: Roche Media News - June 8, 2016 Category: Pharmaceuticals Source Type: news
IASLC pleased by FDA approval of blood test to detect mutations in lung cancer
(International Association for the Study of Lung Cancer) The International Association for the Study of Lung Cancer praises the US Food and Drug Administration's decision to approve the first blood test to detect an oncogenic driver mutation in non-small cell lung cancer. This marks a significant step forward in lung cancer treatment. The cobas EGFR Mutation Test v2 detects epidermal growth factor receptor gene mutations and the FDA approved a blood-based companion diagnostic for the EGFR tyrosine kinase inhibitor erlotinib (Tarceva). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 8, 2016 Category: Global & Universal Source Type: news
Morning Break: Olympic Zika Risk Overblown; Tarceva Marketers Fined; Gut Robot
(MedPage Today) -- Health news and commentary from around the Web, gathered by the MedPage Today staff (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - June 7, 2016 Category: Infectious Diseases Source Type: news
Genentech and OSI to pay $67m to resolve False Claims Act allegations for Tarceva
US-based pharmaceutical companies Genentech and OSI Pharmaceuticals will pay $67m in order to resolve False Claims Act allegations regarding misleading statements made about the effectiveness of Tarceva for treating non-small cell lung cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 6, 2016 Category: Pharmaceuticals Source Type: news
FDA OKs First Liquid Biopsy for Lung Cancer Mutation FDA OKs First Liquid Biopsy for Lung Cancer Mutation
The blood-based genetic test is a companion diagnostic for erlotinib and for use in patients with non-small cell lung cancer. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 1, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer
The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients. Such mutations are present in approximately 10-20 percent of non-small cell lung cancers (NSCLC). (Source: Food and Drug Administration)
Source: Food and Drug Administration - June 1, 2016 Category: American Health Source Type: news
FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer
June 1, 2016 -- The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 1, 2016 Category: Pharmaceuticals Source Type: news
Additional Treatments Offer Little Benefit for Pancreatic Cancer: Study
TUESDAY, May 3, 2016 -- Additional treatments for locally advanced pancreatic cancer don't appear to boost survival, a new French study reports.
Researchers looked at the effects of adding a second drug -- erlotinib (Tarceva) -- to the initial... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 3, 2016 Category: Journals (General) Source Type: news
Chemoradiotherapy vs. chemotherapy for locally advanced pancreatic cancer
(The JAMA Network Journals) In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after four months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 3, 2016 Category: Cancer & Oncology Source Type: news
CHMP recommends EU approval for Roche's Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer
Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) activating mutations. (Source: Roche Investor Update)
Source: Roche Investor Update - April 29, 2016 Category: Pharmaceuticals Source Type: news
CHMP recommends EU approval for Roche's Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer
Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) activating mutations. (Source: Roche Media News)
Source: Roche Media News - April 29, 2016 Category: Pharmaceuticals Source Type: news
FDA approves Gilotrif® (afatinib) as new oral treatment option for patients with squamous cell carcinoma of the lung
• Approval provides a new second-line treatment option for patients with the second largest sub-type of non-small cell lung cancer (NSCLC), representing about 20-30% of NSCLC cases • Approval is based on results of the LUX-Lung 8 study, which showed significantly improved overall survival and progression-free survival compared to Tarceva® (erlotinib) in patients with squamous cell carcinoma of the lung • Gilotrif is already approved in more than 60 countries for the treatment of patients with distinct types of EGFR mutation-positive NSCLC (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - April 14, 2016 Category: Research Source Type: news
